Next-generation Alzheimer’s drug reduces risk of serious brain bleeds
SkimNews Take
A 4-8x lower serious bleed rate suggests next-generation antibody design can widen the therapeutic window for the entire anti-amyloid class, potentially reframing ARIA-related safety as an engineering problem rather than an inherent drug-class limitation.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trontinemab, Roche's antibody drug, clears beta-amyloid by binding to the transferrin receptor — the iron-transport shuttle across the blood-brain barrier — letting it cross far more efficiently than lecanemab and donanemab and be used at lower doses.
- Roche reported that roughly 90% of participants with mild cognitive impairment or mild-to-moderate Alzheimer's went from excessive amyloid to normal levels within six months of monthly trontinemab dosing, versus more than a year for about three-quarters of patients on other amyloid antibodies.
- Trontinemab caused amyloid-related imaging abnormalities (ARIA) — fluid leaks that can trigger serious brain bleeds and seizures — in fewer than 5% of participants, compared with 20% on lecanemab and 40% on donanemab in earlier trials.
- Luka Kulic of Roche in Basel presented the results at the Alzheimer's Association International Conference in London on 14 July; UCL's Nick Fox called the amyloid reduction "remarkable" and predicted trontinemab would match or outperform the licensed therapies.
- Oxford's Luciana Maffei said the better brain entry means trontinemab is "less invasive on your brain" because it doesn't require the high doses that current therapies rely on to trickle across via diffusion.
- Roche is now planning two larger trials to test whether trontinemab slows cognitive decline in early-stage Alzheimer's and whether it prevents the disease in people at high risk; cognitive-outcome data has not yet been released.
Why it matters: If the larger trials confirm cognitive benefits, trontinemab could reach the UK's NHS — where lecanemab and donanemab currently aren't offered due to modest efficacy and cost — because its lower required dose and far fewer ARIA cases could mean fewer infusions and monitoring brain scans, materially driving down treatment costs.
